<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598663</url>
  </required_header>
  <id_info>
    <org_study_id>EUR03</org_study_id>
    <secondary_id>ISRCTN09806152</secondary_id>
    <nct_id>NCT00598663</nct_id>
  </id_info>
  <brief_title>SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c</brief_title>
  <acronym>SWITCH</acronym>
  <official_title>Randomized, Cross Over, Controlled, Multi-centric Study to Assess Whether Type 1 Diabetic Patients in Sub-optimal Glycemic Control Can Improve Using the Continuous Glucose Values of the MiniMed Paradigm REAL-Time Insulin Pump System Versus the MiniMed Paradigm Insulin Pump</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate whether the patients with Type 1 diabetes
      mellitus in sub-optimal glycemic control can achieve better glycemic control by using the
      Medtronic MiniMed Paradigm® REAL-Time Pump System with continuous glucose monitoring versus
      the Medtronic MiniMed Paradigm® REAL-Time Pump alone with Self Monitoring Blood Glucose
      (SMBG).Our null hypothesis is there is a 0% reduction in HbA1c from baseline compared to
      control group, after 6 months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic variability</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in occurrence of hypoglycemia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in euglycaemia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glycaemia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (paeds) and Treatment Satisfaction (adults)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hypo or Diabetic Ketoacidosis events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paradigm Real-Time system: insulin pump with continuous glucose sensing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Paradigm Real-Time insulin pump with self-monitoring blood glucose</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)</intervention_name>
    <description>6 months of pump plus continuous glucose sensing in conjunction to SMBG</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Paradigm Real-Time Insulin Pump System</other_name>
    <other_name>Medtronic MMT-522 or MMT-722 + MMT7707WW</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)</intervention_name>
    <description>insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Paradigm Real-Time insulin pump</other_name>
    <other_name>Guardian Real-Time clinical</other_name>
    <other_name>MMT-522 or MMT-722 + MMT7707WW + CSS7100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus diagnosed for at least 12 months prior to signature of
             informed consent,

          -  Sub-optimal glycemic control (7.5%&lt;HbA1c&lt;9.5%).

          -  Patient treated by continuous subcutaneous insulin infusion (CSII) for at least 6
             months prior signature of informed consent.

          -  Patient treated within the practice of the investigator's center at least 6 months
             prior signature of informed consent.

          -  Patient has no preliminary experience with the sensor function of the Paradigm
             REAL-Time or the Guardian® REAL-Time for the 4 months prior signature of informed
             consent.

        Exclusion Criteria:

          -  Existing pregnancy or intention to conceive (as assessed by investigator).

          -  Hearing or vision impairment so that glucose display and alarms cannot be recognized.

          -  Three or more incidents in the last 12 months of severe hypoglycaemia with documented
             Blood Glucose below 50mg/dL (if possible), resulting in unconsciousness,
             hospitalisation or third party assistance, where recovery follows treatment with
             glucose or glucagon or similar.

          -  History of hypoglycemic unawareness as assessed by the investigator.

          -  Alcohol or drug abuse, other than nicotine.

          -  Documented cutaneous allergy or disease (allergy to sensor or components of the
             sensor, psoriasis, staphylococcus, exanthema etc.).

          -  Any documented concomitant chronic disease known to affect diabetes control (e.g.
             altered renal function, active cancer undergoing treatment, Crohn's disease,
             ulcerative colitis, Mb Addison disease) or any concomitant pharmacological treatment
             that might modify glycemic values (e.g chronic corticosteroid therapy), eating
             disorders and morbid obesity (defined as adults : Body Mass Index &gt;35 and children
             Body Mass Index &gt; 2 standard deviations. for age) as assessed by the investigator.

          -  Any other medical, social or psychological condition that, in the investigator's
             opinion, makes the patient unable to comply with the study protocol and all study
             procedures.

          -  For pediatric subjects: does not have a reliable support person.

          -  Plans to travel for extended periods (3+ weeks) where the devices cannot be supplied
             or replaced and/or medical support is limited (eg. exotic countries, remote places).

          -  Participation in another clinical study, on-going or completed less than 3 months
             prior to signature of Patient Informed Consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. T Battelino</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Hietzing</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Pediatrica, Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Hospitalier de Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Universitari</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Italy</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Slovenia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>January 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2008</study_first_posted>
  <last_update_submitted>September 17, 2010</last_update_submitted>
  <last_update_submitted_qc>September 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hannah Gough / Severine Liabat</name_title>
    <organization>Medtronic</organization>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

